On December 3, 2024, at 4:30 P.M., the United States Securities and Exchange Commission (SEC) declared the S-1 registration statement of Cardio Diagnostics Holdings effective. This marks a significant step for the company, allowing it to proceed with its planned public offering.The effectiveness of the S-1 form indicates that Cardio Diagnostics has met the necessary regulatory requirements to offer its securities to the public. This development is crucial for the company's growth strategy, as it seeks to raise capital through the public markets.Investors should monitor Cardio Diagnostics' next steps, including the pricing and timing of the offering, which will provide further insights into the company's market entry strategy.

On December 3, 2024, at 4:30 P.M., the United States Securities and Exchange Commission (SEC) declared the S-1 registration statement of Cardio Diagnostics Holdings effective. This marks a significant step for the company, allowing it to proceed with its planned public offering.The effectiveness of the S-1 form indicates that Cardio Diagnostics has met the necessary regulatory requirements to offer its securities to the public. This development is crucial for the company's growth strategy, as it seeks to raise capital through the public markets.Investors should monitor Cardio Diagnostics' next steps, including the pricing and timing of the offering, which will provide further insights into the company's market entry strategy.